One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.

Adult Aged Antibodies, Monoclonal, Humanized / adverse effects Arthritis, Psoriatic / diagnosis Body Mass Index Delayed Diagnosis Dermatologic Agents / adverse effects Female Humans Hypersensitivity / etiology Male Medication Adherence Middle Aged Patient Reported Outcome Measures Severity of Illness Index Spondylitis, Ankylosing / diagnosis Treatment Outcome

Ankylosing spondylitis psoriatic arthritis real-life retention rate secukinumab

Journal

Expert opinion on biological therapy

ISSN: 1744-7682

Titre abrégé: Expert Opin Biol Ther

Pays: England

ID NLM: 101125414

Informations de publication

Date de publication:
07 2020

Historique:

pubmed: 14 5 2020

medline: 13 1 2021

entrez: 14 5 2020

Statut: ppublish

Résumé

Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking. Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%). Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.

Sections du résumé

BACKGROUND

Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking.

RESEARCH DESIGN AND METHODS

Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%).

RESULTS

Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R

CONCLUSIONS

Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.

Identifiants

DOI: 10.1080/14712598.2020.1761957 PMID: 32401062

pubmed: 32401062

doi: 10.1080/14712598.2020.1761957

doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0

Dermatologic Agents 0

secukinumab DLG4EML025

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

813-821

Commentaires et corrections

Type : CommentIn